Hims & Hers on Monday released fourth-quarter results that disappointed on gross margin and sparked concerns about the future ...

The Trump administration has started rehiring some of the FDA employees it fired last week, the latest chapter in a haphazard ...

Lilly expands its Zepbound vial offering, as HIMS pulls back on semaglutide, and other biotech news in today's Readout ...

People who have allergies or severe sensitivities to wheat, egg, or milk run the risk of a serious or life-threatening reaction.

After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...

Those rehired by the Trump administration include at least 10 FDA staffers responsible for reviewing the safety of new food ...

The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s (BMS) supplemental biologics licence ...

A deadly listeria outbreak has resulted in a recall of frozen supplemental shakes used at long-term care facilities. The ...

The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded versions due to regulatory changes.

The American Heart Association issued a scientific statement highlighting the significance of mental health in maternal CV ...

Elon Musk is vowing yet again to fire federal workers who don’t respond to an email asking them to list 5 things they ...

Positive data from prospective, multi-center trials confirmed compelling effectiveness and five-year safety with high satisfaction from both ...